Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background Previous retrospective pediatric ulcerative colitis (UC) studies had limited ability to describe disease progression and identify predictors of treatment response. The PROTECT multicentre inception cohort aimed to identify characteristics associated with outcomes following standardized therapy after initial diagnosis. Methods We completed a prospective multicentre inception cohort study at 29 centres in the USA and Canada of paediatric patients aged 4–17 years newly diagnosed with UC who received initial standardized treatment with mesalamine or corticosteroids (CS) guided by the Pediatric UC Activity Index (PUCAI). The key outcomes for this analysis were week 12 CS-free remission, defined as PUCAI<10 and taking only mesalamine, and treatment escalation to anti-TNFα, immunomodulators or colectomy among those initially treated with intravenous (IV) CS. Independent predictors were identified through multivariable logistic regression using a per-protocol approach. Registered with clinicaltrials.gov: NCT01536535 Findings 428 children initiated mesalamine (n=136), oral CS (n=144), or IV CS (n=148) with initial mean ± standard deviation PUCAI of 31±13, 50±14, and 67±14, respectively (p<0.001). By week 12, CS-free remission taking mesalamine only was achieved by 48% (64/132) initiating with mesalamine, 33% (47/141) with oral CS, and 21% (30/143) with IV CS (p<0.001). Treatment escalation was required in 7% (9/132), 15% (21/141), and 36% (52/143), respectively (p<0.001); 8 patients, all initially treated with IV CS, received colectomy. Predictors of week 12 CS-free remission were baseline PUCAI <35 (odds ratio (OR) 2.4, 95% CI 1.4–4.2; p=0.002), higher baseline albumin by 1 g/dL increments among age < 12 years (4.1, 1.9–8.6; p=0.0003), and week 4 remission (6.3, 3.8–10.4; p<0.0001). Predictors of treatment escalation by week 12 in those initially treated with IV CS included baseline total Mayo score ≥11 (2.6, 0.9–7.2; p=0.068), rectal biopsy eosinophil count ≤32/high power field (4.6, 1.6–12.8; p=0.004), rectal biopsy surface villiform changes (3.1, 1.1–8.6; p=0.034) and not achieving week 4 remission (30.2, 6.4–144.2; p<0.0001). Interpretation Our findings provide guidelines to assess response of children newly diagnosed with UC to standardized initial therapy and identify predictors of treatment response and failure. These data suggest that additional therapeutic interventions may be warranted to improve early outcomes, especially in those presenting with severe disease and requiring intravenous corticosteroids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015) · BMJ · doi:10.1136/bmj.g7594 · Cited by 4,388
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Bulletin of the World Health Organization · doi:10.2471/blt.07.045120 · Cited by 1,632
Cited by
Turner, D., Ruemmele, F. M., Orlanski‐Meyer, E., Griffiths, A. M., de Carpi, J. M., Bronsky, J., Veres, G., Aloi, M., Strisciuglio, C., Braegger, C. P., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002035 · Cited by 481
Self-citationHaberman, Y., Karns, R., Dexheimer, P. J., Schirmer, M., Somekh, J., Jurickova, I., Braun, T., Novak, E., Bauman, L., Collins, M. H., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07841-3 · Cited by 371
Self-citationSchirmer, M., Denson, L., Vlamakis, H., Franzosa, E. A., Thomas, S., Gotman, N. M., Rufo, P., Baker, S. S., Sauer, C., Markowitz, J., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.09.009 · Cited by 293
Self-citationVande Casteele, N., Leighton, J. A., Pasha, S. F., Cusimano, F., Mookhoek, A., Hagen, C. E., Rosty, C., Pai, R. K., & Pai, R. K. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab122 · Cited by 52
Machine learning predictive outcomes modeling in inflammatory bowel diseases
Javaid, A., Shahab, O., Adorno, W., Fernandes, P., May, E., & Syed, S. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab187 · Cited by 36
Metadata
- Authors
- Hyams, J. S., Davis, S., Mack, D. R., Boyle, B., Griffiths, A. M., LeLeiko, N. S., Sauer, C. G., Keljo, D. J., Markowitz, J., Baker, S. S., Rosh, J., Baldassano, R. N., Patel, A., Pfefferkorn, M., Otley, A., Heyman, M., Noe, J., Oliva-Hemker, M., Rufo, P., Strople, J., Ziring, D., Guthery, S. L., Sudel, B., Benkov, K., Wali, P., Moulton, D., Evans, J., Kappelman, M. D., Marquis, A., Sylvester, F. A., Collins, M. H., Venkateswaran, S., Dubinsky, M., Tangpricha, V., Spada, K. L., Britt, A., Saul, B., Gotman, N., Wang, J., Serrano, J., Kugathasan, S., Walters, T., & Denson, L. A.
- Venue
- The Lancet Gastroenterology & Hepatology
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 2
- Issue
- 12
- Pages
- 855-868
- ISSN
- 2468-1156 (ISSN-L)
- 2468-1253
- OpenAlex
- W2755016301
- Cited by
- 101
- References
- 3
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study. https://app.cochat.ai/papers/10.1016/s2468-1253(17)30252-2
- The paper
- Hyams, J. S., Davis, S., Mack, D. R., Boyle, B., Griffiths, A. M., LeLeiko, N. S., Sauer, C. G., Keljo, D. J., Markowitz, J., Baker, S. S., Rosh, J., Baldassano, R. N., Patel, A., Pfefferkorn, M., Otley, A., Heyman, M., Noe, J., Oliva-Hemker, M., Rufo, P., . . . Denson, L. A. (2017). Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(17)30252-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.